Shares of Johnson & Johnson /zigman2/quotes/201724570/composite JNJ -1.15% gained 0.4% in premarket trading on Friday after the company said it had submitted an application for its experimental single-dose COVID-19 vaccine to the World Health Organization for emergency authorization. Obtaining an emergency-use listing from the WHO allows J&J's vaccine candidate to be made available through Covax, a global consortium supplying COVID-19 vaccines to lower-income countries. J&J's vaccine, which has not yet been authorized for use in the U.S., is set to be reviewed by a group of vaccine experts next week as part of the Food and Drug Administration's regulatory process. The company also submitted a regulatory application for its coronavirus vaccine in the European Union on Feb. 15. J&J's stock is up 11.3% over the past year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.28% is up 16.3%.